Study of META 10-19 for autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new treatment called META 10-19 for people with autoimmune hemolytic anemia (AIHA) that has not improved with other treatments. It aims to see if this therapy can help control the disease and improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with autoimmune hemolytic anemia (AIHA) or Evans syndrome.
- Your anemia has not improved after trying at least two immunosuppressive treatments, including a medication like rituximab (a type of antibody therapy).
- You have been on steroids (like prednisone) for at least 3 months, unless you couldn't take them for medical reasons.
- You are generally in good health, with adequate organ function (heart, lungs, liver, kidneys).
- You agree to use effective birth control during the study and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This study tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can help control the anemia and reduce the need for ongoing treatments.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This study tests a new drug called enatumab that may help people with a type of autoimmune anemia where the body attacks its own red blood cells. If you have not responded to previous treatments or your condition has returned, this trial might offer a new option to improve your hemoglobin levels.
This early-phase trial tests a new cell therapy (UCAR T cells) that targets specific markers on your immune cells (called CD19 and BCMA) to help stop your body from attacking your own red blood cells. It's for people with autoimmune hemolytic anemia that hasn't responded to multiple standard treatments.
Hear when a new Autoimmune Hemolytic Anemia (AIHA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.